Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences staff profiles

Dr Erwin Lamping

PositionSenior Research Fellow
DepartmentDepartment of Oral Sciences
QualificationsPhD
Research summaryMembrane protein biology
Teaching

Dr Lamping supervises undergraduate and postgraduate students, and enjoys sharing his skills and experience with like-minded individuals.

MembershipsMember of the American Society for Microbiology, the New Zealand Microbiological Society, the New Zealand Society for Biochemistry and Molecular Biology, as well as member of the Oral Microbiology and Dental Health Research Theme and the Webster Centre for Infectious Diseases of the University of Otago.

Research

Experienced in molecular biology with expertise in biochemistry, yeast genetics, and molecular biology, Dr Lamping is particularly interested in studying the structure and function of eukaryotic membrane proteins—especially integral membrane proteins associated with multidrug resistance of fungal pathogens and human cancer cells. The list of membrane proteins includes:

  • The azole antifungal drug target ERG11, an essential enzyme of ergosterol biosynthesis
  • Multidrug efflux pumps of the pleiotropic drug resistance (PDR) and the multidrug resistance (MDR) family of efflux transporters

A significant part of his studies are dedicated to the continuous improvement of the basic molecular biology toolkit that enables scientists to ever more efficiently, precisely, and predictably express heterologous membrane proteins in the eukaryotic model organism Saccharomyces cerevisiae.

In the past decade he helped create and optimise a patented yeast membrane protein expression system used worldwide by over 50 research teams. Dr Lamping used that patented technology to create a suit of yeast strains overexpressing the azole drug target ERG11, as well as many PDR and MDR efflux transporters from human and important fungal pathogens: Candida albicans, C. glabrata, C. krusei, Cryptococcus neoformans, and Aspergillus fumigatus.

These strains have been used successfully for many different research applications funded by national (Marsden, HRC, and FRST), and international funding agencies (NIH, USA; Japan Health Sciences Foundation; and Japan Society for the Promotion of Sciences), and they helped solve the first crystal structure for any full-length cytochrome P450 enzyme, S. cerevisiae Erg11p.

Publications

Lamping, E., Madani, G., Lee, H. J., Niimi, M., & Cannon, R. D. (2017). Structure-function analyses of multidrug tansporters. In R. Prasad (Ed.), Candida albicans: Cellular and molecular biology. (2nd ed.) (pp. 379-406). Springer. doi: 10.1007/978-3-319-50409-4

Lamping, E., Zhu, J.-y., Niimi, M., & Cannon, R. D. (2017). Role of ectopic gene conversion in the evolution of a Candida krusei pleiotropic drug resistance transporter family. Genetics, 205(4), 1619-1639. doi: 10.1534/genetics.116.194811

Reis de Sá, L. F., Toledo, F. T., Gonçalves, A. C., Sousa, B. A., dos Santos, A. A., Brasil, P. F., … Lamping, E., & Ferreira-Pereira, A. (2017). Synthetic organotellurium compounds sensitize drug-resistant Candida albicans clinical isolates to fluconazole. Antimicrobial Agents & Chemotherapy, 61(1), e01231-16. doi: 10.1128/aac.01231-16

Panapruksachat, S., Iwatani, S., Oura, T., Vanittanakom, N., Chindamporn, A., Niimi, K., Niimi, M., Lamping, E., Cannon, R. D., & Kajiwara, S. (2016). Identification and functional characterization of Penicillium marneffei pleiotropic drug resistance transporters ABC1 and ABC2. Medical Mycology, 54, 478-491. doi: 10.1093/mmy/myv117

Watanasrisin, W., Iwatani, S., Oura, T., Tomita, Y., Ikushima, S., Chindamporn, A., Niimi, M., Niimi, K., Lamping, E., Cannon, R. D., & Kajiwara, S. (2016). Identification and characterization of Candida utilis multidrug efflux transporter CuCdr1p. FEMS Yeast Research, 16, fow042. doi: 10.1093/femsyr/fow042

Chapter in Book - Research

Lamping, E., Madani, G., Lee, H. J., Niimi, M., & Cannon, R. D. (2017). Structure-function analyses of multidrug tansporters. In R. Prasad (Ed.), Candida albicans: Cellular and molecular biology. (2nd ed.) (pp. 379-406). Springer. doi: 10.1007/978-3-319-50409-4

Lamping, E., & Cannon, R. D. (2010). Use of a yeast-based membrane protein expression technology to overexpress drug resistance efflux pumps. In G. J. Seymour, M. P. Cullinan & N. C. K. Heng (Eds.), Oral Biology. (pp. 219-250). New York: Springer. doi: 10.1007/978-1-60761-820-1_15

^ Top of page

Journal - Research Article

Lamping, E., Zhu, J.-y., Niimi, M., & Cannon, R. D. (2017). Role of ectopic gene conversion in the evolution of a Candida krusei pleiotropic drug resistance transporter family. Genetics, 205(4), 1619-1639. doi: 10.1534/genetics.116.194811

Reis de Sá, L. F., Toledo, F. T., Gonçalves, A. C., Sousa, B. A., dos Santos, A. A., Brasil, P. F., … Lamping, E., & Ferreira-Pereira, A. (2017). Synthetic organotellurium compounds sensitize drug-resistant Candida albicans clinical isolates to fluconazole. Antimicrobial Agents & Chemotherapy, 61(1), e01231-16. doi: 10.1128/aac.01231-16

Panapruksachat, S., Iwatani, S., Oura, T., Vanittanakom, N., Chindamporn, A., Niimi, K., Niimi, M., Lamping, E., Cannon, R. D., & Kajiwara, S. (2016). Identification and functional characterization of Penicillium marneffei pleiotropic drug resistance transporters ABC1 and ABC2. Medical Mycology, 54, 478-491. doi: 10.1093/mmy/myv117

Watanasrisin, W., Iwatani, S., Oura, T., Tomita, Y., Ikushima, S., Chindamporn, A., Niimi, M., Niimi, K., Lamping, E., Cannon, R. D., & Kajiwara, S. (2016). Identification and characterization of Candida utilis multidrug efflux transporter CuCdr1p. FEMS Yeast Research, 16, fow042. doi: 10.1093/femsyr/fow042

Keniya, M. V., Holmes, A. R., Niimi, M., Lamping, E., Gillet, J.-P., Gottesman, M. M., & Cannon, R. D. (2014). Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. Molecular Pharmaceutics, 11(10), 3452-3462. doi: 10.1021/mp500230b

Lamping, E., Niimi, M., & Cannon, R. D. (2013). Small, synthetic, GC-rich mRNA stem-loop modules 5' proximal to the AUG start-codon predictably tune gene expression in yeast. Microbial Cell Factories, 12, 74. doi: 10.1186/1475-2859-12-74

Niimi, K., Harding, D. R. K., Holmes, A. R., Lamping, E., Niimi, M., Tyndall, J. D. A., Cannon, R. D., & Monk, B. C. (2012). Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a D-octapeptide derivative inhibitor. Molecular Microbiology, 85(4), 747-767. doi: 10.1111/j.1365-2958.2012.08140.x

Tanabe, K., Lamping, E., Nagi, M., Okawada, A., Holmes, A. R., Miyazaki, Y., Cannon, R. D., Monk, B. C., & Niimi, M. (2011). Chimeras of Candida albicans Cdr1p and Cdr2p reveal features of pleiotropic drug resistance transporter structure and function. Molecular Microbiology, 82(2), 416-433. doi: 10.1111/j.1365-2958.2011.07820.x

Holmes, A. R., Keniya, M. V., Ivnitski-Steele, I., Monk, B. C., Lamping, E., Sklar, L. A., & Cannon, R. D. (2011). The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrobial Agents & Chemotherapy, 56(3), 1508-1515. doi: 10.1128/aac.05706-11

Niimi, K., Monk, B. C., Hirai, A., Hatakenaka, K., Umeyama, T., Lamping, E., … Cannon, R. D., & Niimi, M. (2010). Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. Journal of Antimicrobial Chemotherapy, 65, 842-852. doi: 10.1093/jac/dkq073

Lamping, E., Baret, P. V., Holmes, A. R., Monk, B. C., Goffeau, A., & Cannon, R. D. (2010). Fungal PDR transporters: Phylogeny, topology, motifs and function. Fungal Genetics & Biology, 47(2), 127-142. doi: 10.1016/j.fgb.2009.10.007

Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., … Niimi, M., … Monk, B. C. (2009). Efflux-mediated antifungal drug resistance. Clinical Microbiology Reviews, 22(2), 291-321. doi: 10.1128/cmr.00051-08

Ivnitski-Steele, I., Holmes, A. R., Lamping, E., Monk, B. C., Cannon, R. D., & Sklar, L. A. (2009). Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Analytical Biochemistry, 394(1), 87-91. doi: 10.1016/j.ab.2009.07.001

Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009). Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrobial Agents & Chemotherapy, 53(2), 354-369. doi: 10.1128/AAC.01095-08

Holmes, A. R., Lin, Y.-H., Niimi, K., Lamping, E., Keniya, M., Niimi, M., … Monk, B. C., & Cannon, R. D. (2008). ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrobial Agents & Chemotherapy, 52(11), 3851-3862. doi: 10.1128/AAC.00463-08

Tanabe, K., Lamping, E., Adachi, K., Takano, Y., Kawabata, K., Shizuri, Y., Niimi, M., & Uehara, Y. (2007). Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium. Biochemical & Biophysical Research Communications, 364, 990-995.

Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Tanabe, K., & Monk, B. C. (2007). Candida albicans drug resistance: Another way to cope with stress. Microbiology, 153, 3211-3217.

Lamping, E., Monk, B. C., Niimi, K., Holmes, A. R., Tsao, S., Tanabe, K., Niimi, M., … Cannon, R. D. (2007). Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryotic Cell, 6(7), 1150-1165.

Holmes, A. R., Tsao, S., Ong, S.-W., Lamping, E., Niimi, K., Monk, B. C., Niimi, M., … Cannon, R. D. (2006). Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2. Molecular Microbiology, 62(1), 170-186.

Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006). Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrobial Agents & Chemotherapy, 50(4), 1148-1155.

Niimi, M., Tanabe, K., Wada, S.-I., Yamazaki, A., Uehara, Y., Niimi, K., Lamping, E., Holmes, A. R., Monk, B. C., & Cannon, R. D. (2005). ABC transporters of pathogenic fungi: Recent advances in functional analyses. Japanese Journal of Medical Mycology / Nippon Ishinkin Gakkai Zasshi, 46(4), 249-260.

Wada, S.-I., Tanabe, K., Yamazaki, A., Niimi, M., Uehara, Y., Niimi, K., Lamping, E., Cannon, R. D., & Monk, B. C. (2005). Phosphorylation of Candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability. Journal of Biological Chemistry, 280(1), 94-103.

Lamping, E., Tanabe, K., Niimi, M., Uehara, Y., Monk, B. C., & Cannon, R. D. (2005). Characterization of the Saccharomyces cerevisiae sec6-41 mutation and tools to create S. cerevisiae strains containing the sec6-4 allele. Gene, 361, 57-66.

Niimi, M., Wada, S.-I., Tanabe, K., Kaneko, A., Takano, Y., Umeyama, T., … Lamping, E., Niimi, K., Tsao, S., Holmes, A. R., Monk, B. C., & Cannon, R. D. (2005). Functional analysis of fungal drug efflux transporters by heterologous expression in Saccharomyces cerevisiae. Japanese Journal of Infectious Diseases, 58, 1-7.

^ Top of page

Journal - Research Other

Holmes, A. R., Tsao, S., Lamping, E., Niimi, K., Monk, B. C., Tanabe, K., Niimi, M., & Cannon, R. D. (2006). Amino acid residues affecting drug pump function in Candida albicans: C. albicans drug pump function [Review]. Japanese Journal of Medical Mycology / Nippon Ishinkin Gakkai Zasshi, 47(4), 275-281.

More publications...